Merit Medical Systems - MMSI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $72.00
  • Forecasted Upside: -1.42 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$73.04
▲ +0.52 (0.72%)

This chart shows the closing price for MMSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merit Medical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MMSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MMSI

Analyst Price Target is $72.00
▼ -1.42% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Merit Medical Systems in the last 3 months. The average price target is $72.00, with a high forecast of $78.00 and a low forecast of $63.00. The average price target represents a -1.42% upside from the last price of $73.04.

This chart shows the closing price for MMSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Merit Medical Systems. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2022Canaccord Genuity GroupBoost Target$69.00 ➝ $73.00Low
10/28/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$63.00 ➝ $69.00Low
10/27/2022Raymond JamesBoost TargetOutperform$71.00 ➝ $72.00Low
10/27/2022Piper SandlerBoost Target$70.00 ➝ $73.00Low
10/14/2022Canaccord Genuity GroupLower Target$69.00 ➝ $63.00Low
10/14/2022Canaccord Genuity GroupLower TargetBuy$69.00 ➝ $63.00Low
9/2/2022Canaccord Genuity GroupBoost TargetBuy$67.00 ➝ $69.00Low
9/2/2022Canaccord Genuity GroupBoost Target$67.00 ➝ $69.00Low
8/1/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$74.00 ➝ $67.00Low
7/1/2022Piper SandlerLower Target$75.00 ➝ $70.00Low
4/28/2022Barrington ResearchLower Target$82.00 ➝ $78.00High
2/25/2022Barrington ResearchBoost TargetBuy$78.00 ➝ $82.00High
2/25/2022Raymond JamesLower TargetOutperform$73.00 ➝ $72.00High
2/25/2022Needham & Company LLCLower TargetBuy$83.00 ➝ $73.00High
2/25/2022Piper SandlerLower Target$79.00 ➝ $75.00High
10/29/2021Wells Fargo & CompanyBoost TargetEqual Weight$68.00 ➝ $74.00Medium
9/30/2021Barrington ResearchInitiated CoverageBuy$79.00Medium
7/30/2021Barrington ResearchBoost TargetOutperform$71.00 ➝ $79.00High
7/30/2021Raymond JamesBoost TargetOutperform$69.00 ➝ $73.00High
7/30/2021Needham & Company LLCBoost TargetBuy$73.00 ➝ $83.00High
7/30/2021Wells Fargo & CompanyBoost TargetEqual Weight$65.00 ➝ $68.00High
7/30/2021Piper SandlerBoost TargetOverweight$73.00 ➝ $79.00High
4/30/2021Needham & Company LLCBoost TargetBuy$68.00 ➝ $73.00High
4/30/2021Barrington ResearchBoost TargetOutperform$63.00 ➝ $71.00Low
4/30/2021Raymond JamesBoost TargetOutperform$61.00 ➝ $69.00Low
3/3/2021Raymond JamesBoost TargetOutperform$60.00 ➝ $61.00Medium
2/25/2021Needham & Company LLCBoost TargetBuy$65.00 ➝ $68.00High
2/25/2021Raymond JamesReiterated RatingOutperform$60.00 ➝ $61.00High
2/25/2021Barrington ResearchBoost TargetOutperform$62.00 ➝ $63.00High
1/5/2021Needham & Company LLCUpgradeHold ➝ Buy$65.00N/A
11/11/2020Wells Fargo & CompanyBoost TargetEqual Weight$51.00 ➝ $58.00Low
11/11/2020OppenheimerBoost TargetOutperform$55.00 ➝ $60.00Low
11/11/2020Raymond JamesBoost TargetOutperform$57.00 ➝ $60.00High
10/29/2020SidotiBoost TargetBuy$63.00 ➝ $72.00Medium
10/29/2020Barrington ResearchBoost TargetOutperform$54.00 ➝ $62.00High
10/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$42.00 ➝ $51.00High
10/29/2020OppenheimerBoost TargetOutperform$50.00 ➝ $55.00High
10/29/2020Raymond JamesBoost TargetPositive ➝ Outperform$51.00 ➝ $57.00High
10/29/2020Piper SandlerBoost TargetOverweight$55.00 ➝ $62.00High
9/28/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$42.00High
9/14/2020Raymond JamesReiterated RatingBuyLow
7/30/2020OppenheimerBoost TargetOutperform$46.00 ➝ $50.00Low
7/30/2020Raymond JamesBoost TargetOutperform$49.00 ➝ $51.00Low
7/30/2020Barrington ResearchBoost TargetOutperform$49.00 ➝ $54.00Low
7/30/2020Needham & Company LLCReiterated RatingHoldLow
7/30/2020Piper SandlerBoost TargetPositive ➝ Overweight$50.00 ➝ $55.00Low
6/1/2020SidotiBoost TargetBuy$55.00 ➝ $63.00Medium
5/27/2020Barrington ResearchBoost TargetOutperform$42.00 ➝ $49.00Low
5/27/2020Raymond JamesBoost TargetOutperform$46.00 ➝ $49.00Low
4/24/2020Barrington ResearchUpgradeBuy$42.00Low
4/24/2020Raymond JamesBoost TargetOutperform$44.00 ➝ $46.00Low
4/24/2020Wells Fargo & CompanyBoost TargetUnderweight$33.00 ➝ $37.00High
4/24/2020OppenheimerReiterated RatingBuy$46.00High
4/20/2020Barrington ResearchUpgradeMarket Perform ➝ OutperformMedium
2/26/2020Needham & Company LLCReiterated RatingHoldHigh
2/25/2020Piper SandlerReiterated RatingOverweight$42.00 ➝ $50.00High
2/25/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
2/25/2020Wells Fargo & CompanyBoost TargetUnderweight$26.00 ➝ $33.00High
2/25/2020Raymond JamesBoost TargetOutperform$43.00 ➝ $47.00High
2/7/2020OppenheimerBoost Target$32.00 ➝ $43.00Low
2/3/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$43.00Medium
1/14/2020Piper SandlerBoost Target$30.00 ➝ $42.00Medium
12/12/2019Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$26.00High
10/31/2019Barrington ResearchLower TargetOutperform$59.00 ➝ $31.00High
10/31/2019Needham & Company LLCReiterated RatingHoldHigh
10/31/2019Piper Jaffray CompaniesLower TargetOverweight$40.00 ➝ $30.00High
9/23/2019OppenheimerInitiated CoverageOutperform$40.00Low
9/17/2019Piper Jaffray CompaniesLower TargetOverweight$58.00 ➝ $40.00High
9/13/2019Bank of AmericaSet TargetHold$37.00Medium
9/12/2019Barrington ResearchInitiated CoverageBuy$59.00Low
9/10/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
7/26/2019SidotiSet TargetBuy$74.00N/A
7/26/2019Barrington ResearchReiterated RatingBuy$59.00High
7/26/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
7/26/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$71.00 ➝ $46.00High
7/26/2019Piper Jaffray CompaniesSet TargetOverweight$75.00 ➝ $58.00High
4/25/2019Needham & Company LLCReiterated RatingBuyHigh
12/17/2018Needham & Company LLCReiterated RatingBuy$73.00High
10/2/2018SidotiSet TargetBuy$79.00Low
10/2/2018Piper Jaffray CompaniesBoost TargetOverweight$58.00 ➝ $72.00Low
10/2/2018Barrington ResearchBoost TargetOutperform$69.00Low
10/2/2018Needham & Company LLCBoost TargetBuy ➝ Buy$67.00 ➝ $73.00High
8/27/2018SunTrust BanksBoost TargetBuy$68.00Low
8/7/2018Bank of AmericaDowngradeBuy ➝ Underperform$64.00High
7/24/2018Barrington ResearchBoost TargetOutperform$50.00 ➝ $61.00High
7/24/2018Raymond JamesBoost TargetOutperform ➝ Outperform$59.00 ➝ $61.00Low
7/24/2018Needham & Company LLCBoost TargetBuy$54.00 ➝ $67.00High
6/4/2018Wells Fargo & CompanyBoost TargetOutperform ➝ Outperform$53.00 ➝ $58.00Medium
6/1/2018Needham & Company LLCReiterated RatingBuy$54.00Low
6/1/2018SunTrust BanksReiterated RatingBuy$55.00 ➝ $62.00Low
5/18/2018SunTrust BanksBoost TargetBuy$55.00 ➝ $62.00Low
4/26/2018Raymond JamesBoost TargetOutperform ➝ Outperform$50.00 ➝ $51.00High
4/26/2018Needham & Company LLCBoost TargetBuy ➝ Buy$53.00 ➝ $54.00High
4/20/2018Needham & Company LLCInitiated CoverageBuy$53.00 ➝ $53.00Low
3/7/2018SunTrust BanksBoost TargetBuy$1.64 ➝ $55.00Low
3/1/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$50.00High
(Data available from 12/4/2017 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/8/2022
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/5/2022
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/5/2022
  • 13 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 10 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/4/2022

Current Sentiment

  • 10 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Merit Medical Systems logo
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Read More

Today's Range

Now: $73.04
Low: $71.31
High: $73.69

50 Day Range

MA: $64.04
Low: $54.30
High: $73.04

52 Week Range

Now: $73.04
Low: $50.46
High: $73.69

Volume

351,064 shs

Average Volume

232,686 shs

Market Capitalization

$4.16 billion

P/E Ratio

67.63

Dividend Yield

N/A

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Merit Medical Systems?

The following Wall Street sell-side analysts have issued research reports on Merit Medical Systems in the last year: Barrington Research, Canaccord Genuity Group Inc., Needham & Company LLC, Piper Sandler, Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for MMSI.

What is the current price target for Merit Medical Systems?

6 Wall Street analysts have set twelve-month price targets for Merit Medical Systems in the last year. Their average twelve-month price target is $72.00, suggesting a possible downside of 1.4%. Barrington Research has the highest price target set, predicting MMSI will reach $78.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $63.00 for Merit Medical Systems in the next year.
View the latest price targets for MMSI.

What is the current consensus analyst rating for Merit Medical Systems?

Merit Medical Systems currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MMSI will outperform the market and that investors should add to their positions of Merit Medical Systems.
View the latest ratings for MMSI.

What other companies compete with Merit Medical Systems?

Other companies that are similar to Merit Medical Systems include Haemonetics, ICU Medical, Atrion, Inari Medical and Integra LifeSciences. Learn More about companies similar to Merit Medical Systems.

How do I contact Merit Medical Systems' investor relations team?

Merit Medical Systems' physical mailing address is 1600 WEST MERIT PARK WAY, SOUTH JORDAN UT, 84095. The medical instruments supplier's listed phone number is (801) 253-1600 and its investor relations email address is [email protected] The official website for Merit Medical Systems is www.merit.com. Learn More about contacing Merit Medical Systems investor relations.